Stifel Nicolaus Begins Coverage on Structure Therapeutics (NASDAQ:GPCR)

Equities researchers at Stifel Nicolaus initiated coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a report issued on Wednesday, Marketbeat.com reports. The firm set a “buy” rating and a $50.00 price target on the stock. Stifel Nicolaus’ target price indicates a potential upside of 84.91% from the stock’s previous close.

A number of other equities analysts also recently issued reports on GPCR. JMP Securities reiterated a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a report on Monday, September 23rd. Morgan Stanley initiated coverage on Structure Therapeutics in a research note on Monday, September 23rd. They set an “overweight” rating and a $118.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Thursday, December 19th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Price Performance

NASDAQ:GPCR opened at $27.04 on Wednesday. The firm has a market cap of $1.55 billion, a PE ratio of -36.54 and a beta of -2.78. The company has a 50-day moving average of $32.35 and a 200 day moving average of $36.63. Structure Therapeutics has a 1-year low of $25.90 and a 1-year high of $62.74.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in GPCR. GAMMA Investing LLC raised its position in shares of Structure Therapeutics by 4,155.6% in the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock valued at $31,000 after purchasing an additional 1,122 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Structure Therapeutics by 302.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 33,936 shares of the company’s stock valued at $1,489,000 after purchasing an additional 25,500 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Structure Therapeutics by 230.0% in the third quarter. Principal Financial Group Inc. now owns 545,359 shares of the company’s stock worth $23,936,000 after buying an additional 380,115 shares during the last quarter. Exome Asset Management LLC acquired a new stake in shares of Structure Therapeutics during the third quarter worth $5,274,000. Finally, Franklin Resources Inc. grew its holdings in shares of Structure Therapeutics by 9.4% during the third quarter. Franklin Resources Inc. now owns 706,106 shares of the company’s stock valued at $30,991,000 after buying an additional 60,397 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.